- Home
- CTO vs LXEO Comparison
CTO vs LXEO Comparison
Compare CTO & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTO | LXEO |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.7M | 731.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CTO | LXEO |
|---|---|---|
| Price | $19.58 | $7.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $21.50 | $18.60 |
| AVG Volume (30 Days) | 256.1K | ★ 605.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | ★ 75.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $1.45 |
| 52 Week High | $20.25 | $10.99 |
Technical Indicators
Market Signals| Indicator | CTO | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 56.03 |
| Support Level | $17.29 | $6.90 |
| Resistance Level | $20.25 | $7.72 |
| Average True Range (ATR) | 0.42 | 0.46 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 48.53 | 74.18 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.